HAEMONETICS CORP

For the period ended Dec 28, 2024. Filed Feb 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 28, 2024 · Filed Feb 6, 2025

HAE$118.21-1.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

ITEM 1. Financial Statements

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(Unaudited in thousands, except per share data)

	Three Months Ended		Nine Months Ended
	December 28,2024	December 30,2023	December 28,2024	December 30,2023
Net revenues	$348,542	$336,250	$1,030,225	$965,765
Cost of goods sold	154,995	158,383	474,317	450,123
Gross profit	193,547	177,867	555,908	515,642
Operating expenses:
Research and development	15,829	13,265	46,808	38,578
Selling, general and administrative	106,459	111,713	321,653	320,518
Amortization of acquired intangible assets	12,230	6,911	36,965	21,606
Total operating expenses	134,518	131,889	405,426	380,702
Operating income	59,029	45,978	150,482	134,940
Interest and other expense, net	(9,112)	(1,949)	(9,148)	(6,489)
Income before provision for income taxes	49,917	44,029	141,334	128,451
Provision for income taxes	12,423	12,788	31,636	31,260
Net income	$37,494	$31,241	$109,698	$97,191
Net income per share - basic	$0.75	$0.62	$2.16	$1.92
Net income per share - diluted	$0.74	$0.61	$2.14	$1.89
Weighted average shares outstanding
Basic	50,286	50,768	50,709	50,679
Diluted	50,639	51,445	51,148	51,394
Comprehensive income	$16,557	$39,564	$89,829	$103,190

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.